Menu
Search
|

Menu

Close
X

Rosetta Genomics Ltd ROSG.OQ (NASDAQ Stock Exchange Capital Market)

0.30 USD
-0.06 (-16.36%)
As of Feb 23
chart
Previous Close 0.36
Open 0.30
Volume 167,386
3m Avg Volume 51,932
Today’s High 0.32
Today’s Low 0.26
52 Week High 5.74
52 Week Low 0.26
Shares Outstanding (mil) 5.93
Market Capitalization (mil) 1.79
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY16
9
FY15
8
EPS (USD)
FY16
-9.306
FY15
-8.075
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.62
Price to Sales (TTM)
vs sector
0.19
8.35
Price to Book (MRQ)
vs sector
0.13
5.22
Price to Cash Flow (TTM)
vs sector
--
25.88
Total Debt to Equity (MRQ)
vs sector
2.72
15.84
LT Debt to Equity (MRQ)
vs sector
1.47
12.39
Return on Investment (TTM)
vs sector
-116.88
13.63
Return on Equity (TTM)
vs sector
-135.07
15.39

EXECUTIVE LEADERSHIP

Brian Markison
Chairman of the Board, Since 2011
Salary: --
Bonus: --
Kenneth Berlin
President, Chief Executive Officer, Since 2011
Salary: --
Bonus: --
Ron Kalfus
Chief Financial Officer, Since 2012
Salary: --
Bonus: --
Douglas Sites
Executive Vice President - Sales and Marketing, Since 2014
Salary: --
Bonus: --
Dganit Bar
Chief Scientific Officer, Since 2012
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

10 Plaut Street, Science Park, P
REHOVOT     7670609

Phone: +9727.32220700

Rosetta Genomics Ltd. is engaged in developing and commercializing new diagnostic tests based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA) and protein biomarkers and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH). It is marketing and selling over four diagnostic tests based on its microRNA technologies, which include RosettaGX Cancer Origin, mi-LUNG, mi-KIDNEY and RosettaGX Reveal. Its therapeutic pipeline consists of the projects, which include Rimonim Consortium and Magneton Project. It focuses on developing diagnostic assay, RosettaGX Reveal V2. It is also focusing on developing Bladder cancer risk stratification. Its PersonalizeDx is focused on the detection of genomic changes through FISH technology, which helps to detect cancer.

SPONSORED STORIES